Roche Forges Ahead With Taspoglutide Despite Other GLP-1 Cancer Signal
This article was originally published in Pharmaceutical Approvals Monthly
Roche is forging ahead with its glucagon-like peptide-1 analog taspoglutide despite reports of adenomas (benign tumors) in animal studies and the stumbling block Novo Nordisk hit with its competing type 2 diabetes product Victoza (liraglutide) due to a thyroid cancer signal in animals
You may also be interested in...
Liraglutide’s cardiovascular safety profile gets support from a majority of an FDA advisory committee, but a preclinical thyroid cancer risk results in a tied vote on the approvability of Novo Nordisk’s type 2 diabetes drug.
FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.